Actualités

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor

Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.

(Bloomberg) -- The peptide boom has all the markings of a mainstream wellness craze: podcast evangelists, celebrity converts and a billion-dollar market promising shortcuts to weight loss, muscle gain and a longer life. One major hurdle: actually buying them.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on

Find insight on Eli Lilly, GSK, Intuitive Surgical and more in the latest Market Talks covering the Health Care sector.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...

Eli Lilly (LLY) has seen a lot of bullish calls from Wall Street in July. Guggenheim, Truist, Bank of America, Bernstein, and JPMorgan all raised their price targets in the first half of the month. Then UBSwent higher than nearly all of them. UBS's call is worth watching closely because ...

(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus

Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.

(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.

Wall Street is waiting for evidence that AI can change the economics of making drugs. In the lab, AI is already delivering a tangible leap in efficiency, predicting how proteins fold, identifying potential drug targets, and screening millions of molecules virtually. Traditionally, scientists have selected drug targets largely by hand, drawing on the body of research they know best to decide which proteins might matter in a disease, then spending months or years testing those hypotheses in the lab.

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.

Find insight on Eli Lilly, Vertex Pharmaceuticals, Raffles Medical and more in the latest Market Talks covering the health care sector.

July 7 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to capture a slice of a fast-growing sector dominated by Novo Nordisk and Eli Lilly.

As the Nasdaq shakes off a recent spat of volatility, Eli Lilly, Affirm. Twilio and BillionToOne come into focus.

Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its weight-loss drugs. Away from that spotlight, the drugmaker made changes to a smaller corner of its business in its second-largest market. On June 30, Lilly agreed to hand a Chinese partner full ...

Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier.

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.

Here's what investors should do amid the stock market's divergent signals. Eli Lilly is strong while Tesla EV sales loom.

Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

A coalition of employers and state governments says it is developing a sweeping strategy to help workers respond to the AI age.

When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly's 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company's hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look.

Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.